New antibody therapy aims to shield kids with rare immune disorder
Disease control
Ongoing
This study tests a medicine called Kedrion IVIg 10% in 30 children with primary immunodeficiency disease (PID), a condition where the immune system cannot fight infections well. The treatment provides antibodies to help prevent serious bacterial infections. The goal is to see if …
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated May 17, 2026 08:51 UTC